Bristol-Myers Squibb Company and Gilead Sciences, Inc.: A Detailed Gross Profit Analysis

Pharma Giants' Profit Trends: A Decade in Review

__timestampBristol-Myers Squibb CompanyGilead Sciences, Inc.
Wednesday, January 1, 20141194700000021102000000
Thursday, January 1, 20151265100000028633000000
Friday, January 1, 20161448100000026129000000
Sunday, January 1, 20171471000000021736000000
Monday, January 1, 20181601400000017274000000
Tuesday, January 1, 20191806700000017774000000
Wednesday, January 1, 20203074500000020117000000
Friday, January 1, 20213644500000020704000000
Saturday, January 1, 20223602200000021624000000
Sunday, January 1, 20233431300000020618000000
Monday, January 1, 20243635100000078200000
Loading chart...

Infusing magic into the data realm

A Decade of Gross Profit Trends: Bristol-Myers Squibb vs. Gilead Sciences

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. From 2014 to 2023, Bristol-Myers Squibb Company and Gilead Sciences, Inc. have showcased intriguing gross profit trajectories. Bristol-Myers Squibb's gross profit surged by approximately 187% over this period, peaking in 2021 with a remarkable 36.4 billion. This growth reflects strategic expansions and successful product launches. In contrast, Gilead Sciences experienced a more modest fluctuation, with a peak in 2015 and a subsequent decline, ending 2023 with a gross profit of 20.6 billion. This represents a 27% decrease from its 2015 high. These trends highlight the dynamic nature of the pharmaceutical sector, where innovation and market adaptation are key. As we delve into these financial narratives, it becomes evident that strategic foresight and adaptability are paramount for sustained success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025